Y Lynn Wang Selected Research

Y Lynn Wang Research Topics

Disease

10	Neoplasms (Cancer) 10/2023 - 02/2007
7	Lymphoma (Lymphomas) 09/2023 - 09/2006
7	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2021 - 06/2014
5	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 12/2021 - 09/2014
4	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 09/2013 - 05/2006
3	Disease Progression 09/2023 - 12/2008
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2018 - 12/2015
2	B-Cell Lymphoma (Lymphoma, B Cell) 08/2017 - 09/2010
2	Polycythemia Vera 04/2012 - 02/2011
2	Starvation 02/2007 - 09/2006
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2023
1	Residual Neoplasm 01/2021
1	Inflammation (Inflammations) 01/2019
1	Leukemia 05/2017
1	Primary Effusion Lymphoma 10/2013
1	Splenomegaly 02/2011
1	Primary Myelofibrosis (Myelosclerosis) 02/2011
1	Microsatellite Instability 04/2009
1	Colorectal Neoplasms (Colorectal Cancer) 04/2009
1	Multiple Myeloma 12/2008
1	Carcinogenesis 01/2008
1	Myeloproliferative Disorders (Myeloproliferative Disorder) 04/2007
1	T-Cell Lymphoma (Lymphoma, T Cell) 02/2007
1	Type 2 Diabetes Mellitus (MODY) 08/2002

Drug/Important Bio-Agent (IBA)

11	ibrutinibIBA 09/2023 - 06/2014
4	Phosphotransferases (Kinase)IBA 01/2019 - 05/2006
4	PPAR gammaIBA 04/2009 - 09/2006
3	Agammaglobulinaemia Tyrosine KinaseIBA 01/2023 - 01/2019
3	4- (cyclopropylamino)- 2- ((4- (4- (ethylsulfonyl)piperazin- 1- yl)phenyl)amino)pyrimidine- 5- carboxamideIBA 01/2019 - 12/2015
3	Imatinib Mesylate (Gleevec)FDA Link 09/2013 - 10/2011
2	DNA (Deoxyribonucleic Acid)IBA 12/2023 - 10/2023
2	Proteins (Proteins, Gene)FDA Link 10/2013 - 12/2008
2	ThiazolidinedionesIBA 01/2008 - 08/2002
1	Alkylating AgentsIBA 09/2023
1	Rituximab (Mabthera)FDA Link 09/2023
1	vecabrutinibIBA 09/2023
1	Bendamustine Hydrochloride FDA Link 09/2023
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	Janus Kinase InhibitorsIBA 01/2019
1	selinexorIBA 12/2018
1	Therapeutic UsesIBA 01/2018
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2018
1	idelalisibIBA 08/2017
1	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 01/2016
1	Genetic Markers (Genetic Marker)IBA 10/2015
1	purineIBA 10/2013
1	6- amino- 8- ((6- iodo- 1,3- benzodioxol- 5- yl)thio)- N- (1- methylethyl)- 9H-purine-9-propanamineIBA 10/2013
1	Tyrosine Kinase InhibitorsIBA 09/2013
1	Dasatinib (BMS 354825)FDA Link 04/2012
1	Hydroxyurea (Hydrea)FDA LinkGeneric 04/2012
1	Busulfan (Busulfex)FDA Link 04/2012
1	InterferonsIBA 04/2012
1	Phosphorus (Red Phosphorus)IBA 04/2012
1	2- (2- aminocyclohexylamino)- 4- (m- tolylamino)pyrimidine- 5- carboxamideIBA 12/2011
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 10/2011
1	MicroRNAs (MicroRNA)IBA 09/2010
1	Fatty Acid Synthases (Fatty Acid Synthase)IBA 04/2009
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 04/2009
1	beta CateninIBA 04/2009
1	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2008
1	Janus Kinase 2IBA 04/2007
1	LigandsIBA 02/2007
1	Antineoplastic Agents (Antineoplastics)IBA 02/2007
1	GlucuronidaseIBA 07/2006

Therapy/Procedure

9	Therapeutics 01/2021 - 02/2007
1	Ligation 01/2018
1	Drug Therapy (Chemotherapy) 01/2016
1	Immunomodulation 12/2008